TimesSquare Capital Management LLC Buys Shares of 261,344 Enliven Therapeutics, Inc. $ELVN

TimesSquare Capital Management LLC bought a new position in shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 261,344 shares of the company’s stock, valued at approximately $13,263,000.

A number of other institutional investors have also made changes to their positions in ELVN. KBC Group NV purchased a new stake in shares of Enliven Therapeutics in the 1st quarter valued at approximately $38,000. Mirae Asset Global Investments Co. Ltd. boosted its position in shares of Enliven Therapeutics by 25.9% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,884 shares of the company’s stock worth $44,000 after purchasing an additional 594 shares during the period. BNP Paribas Financial Markets boosted its position in shares of Enliven Therapeutics by 33.3% during the 2nd quarter. BNP Paribas Financial Markets now owns 3,722 shares of the company’s stock worth $75,000 after purchasing an additional 930 shares during the period. Los Angeles Capital Management LLC acquired a new stake in Enliven Therapeutics in the 4th quarter valued at approximately $83,000. Finally, Quantbot Technologies LP raised its position in Enliven Therapeutics by 47.1% in the second quarter. Quantbot Technologies LP now owns 4,477 shares of the company’s stock valued at $90,000 after purchasing an additional 1,434 shares during the period. 95.08% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

ELVN has been the topic of a number of research reports. Stifel Nicolaus upped their price target on Enliven Therapeutics from $80.00 to $82.00 and gave the stock a “buy” rating in a research note on Thursday, August 6th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Enliven Therapeutics in a research note on Friday, July 17th. The Goldman Sachs Group boosted their price objective on Enliven Therapeutics from $67.00 to $80.00 and gave the company a “buy” rating in a report on Thursday, August 6th. JonesTrading increased their target price on Enliven Therapeutics from $45.00 to $70.00 and gave the stock a “buy” rating in a research note on Monday, June 29th. Finally, Mizuho raised their target price on Enliven Therapeutics from $45.00 to $62.00 and gave the company an “outperform” rating in a report on Tuesday, June 2nd. Six investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, Enliven Therapeutics has a consensus rating of “Moderate Buy” and an average price target of $72.67.

Insider Buying and Selling

In other Enliven Therapeutics news, Director Mika K. Derynck sold 158,795 shares of the company’s stock in a transaction dated Tuesday, August 4th. The stock was sold at an average price of $60.21, for a total transaction of $9,561,046.95. Following the sale, the director owned 87,373 shares in the company, valued at $5,260,728.33. This represents a 64.51% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Lori Anne Kunkel sold 10,000 shares of the stock in a transaction dated Friday, June 5th. The shares were sold at an average price of $34.54, for a total value of $345,400.00. Following the completion of the sale, the director directly owned 51,884 shares in the company, valued at $1,792,073.36. This represents a 16.16% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 190,831 shares of company stock valued at $10,991,723 in the last three months. 3.00% of the stock is owned by corporate insiders.

Enliven Therapeutics Stock Up 1.2%

Enliven Therapeutics stock opened at $59.53 on Tuesday. Enliven Therapeutics, Inc. has a 52-week low of $14.78 and a 52-week high of $62.32. The firm has a market cap of $4.36 billion, a PE ratio of -35.65 and a beta of 0.27. The company’s 50 day moving average is $51.42 and its two-hundred day moving average is $41.13.

Enliven Therapeutics (NASDAQ:ELVN) last posted its quarterly earnings data on Wednesday, August 5th. The company reported ($0.49) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.10). On average, equities research analysts anticipate that Enliven Therapeutics, Inc. will post -1.67 earnings per share for the current fiscal year.

Enliven Therapeutics Company Profile

Enliven Therapeutics is a clinical-stage biotechnology company focused on developing small-molecule therapies that harness induced proximity mechanisms to selectively target and degrade disease-causing proteins in cancer. Leveraging its proprietary Induced Proximity platform, the company designs molecular glues and related modalities to recruit endogenous cellular machinery for targeted protein degradation, with the goal of treating malignancies driven by so-called “undruggable” oncogenic factors.

The company’s pipeline comprises several early-stage programs directed at key oncogenic drivers across hematologic and solid tumor indications.